<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03724968</url>
  </required_header>
  <id_info>
    <org_study_id>VICC MEL 18114</org_study_id>
    <secondary_id>NCI-2018-02469</secondary_id>
    <nct_id>NCT03724968</nct_id>
  </id_info>
  <brief_title>Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression</brief_title>
  <official_title>A Phase II Two-Arm Open-Label Study of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elizabeth Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized two arm Phase 2 study of intravenous nivolumab plus&#xD;
      intravenous ipilimumab or intravenous relatlimab in patients with metastatic melanoma&#xD;
      stratified by MHC-II expression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      • To evaluate the efficacy, measured by change in activated GZMB+ CD8+ T-cell density&#xD;
      intratumorally, of two immunotherapy regimens in patients with advanced melanoma:&#xD;
&#xD;
        -  nivolumab plus relatlimab in patients with MHC-II (+) melanoma, and&#xD;
&#xD;
        -  nivolumab plus ipilimumab in patients with MHC-II (-) melanoma.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      • To evaluate the response rate, median progression free survival, overall survival, and&#xD;
      safety and tolerability of nivolumab plus relatlimab in patients with MHC-II (+) melanoma,&#xD;
      and of nivolumab plus ipilimumab in patients with MHC-II (-) melanoma.&#xD;
&#xD;
      Exploratory Objectives&#xD;
&#xD;
        -  To explore potential associations of biomarkers with clinical efficacy and/or incidence&#xD;
           of adverse events due to study drug by analyzing biomarker measures within the&#xD;
           peripheral blood and tumor microenvironment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Loss of funding&#xD;
  </why_stopped>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Actual">May 28, 2020</completion_date>
  <primary_completion_date type="Actual">May 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Activated GZMB+ CD8+T-cell Density Intratumorally, of Two Immunotherapy Regimens</measure>
    <time_frame>Approximately 16 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Approximately 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival</measure>
    <time_frame>Approximately 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>Approximately 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 5.0</measure>
    <time_frame>Up to 30 days from last dose of drugs (average of 13 cycles)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Advanced Melanoma</condition>
  <condition>Metastatic Melanoma Stratified by MHC-II Expression</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab and Relatlimab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab and Ipilimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab will be given by vein on day 1 of each cycle.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relatlimab</intervention_name>
    <description>Relatlimab will be given by vein on day 1 of each 28-day cycle</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated written informed consent.&#xD;
&#xD;
          -  ≥ 18 years of age at the time of informed consent.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Histologically confirmed locally advanced/unresectable or metastatic melanoma.&#xD;
&#xD;
          -  Patients who have received prior anti-CTLA-4 or anti-PD-1/PD-L1 for adjuvant treatment&#xD;
             of melanoma are eligible if &gt; 6 months have elapsed between the last dose of adjuvant&#xD;
             treatment and starting this study - provided there is no history of life-threatening&#xD;
             toxicity related to such prior treatment, or such toxicity is unlikely to re-occur&#xD;
             with standard countermeasures (e.g. hormone replacement after endocrinopathy).&#xD;
&#xD;
          -  Patients who have received adjuvant therapy with interferon and/or a BRAF inhibitor&#xD;
             and/or MEK inhibitor for adjuvant therapy are permitted to enroll.&#xD;
&#xD;
          -  At least one measureable target lesion as defined by RECIST 1.1 which can be followed&#xD;
             byCT or MRI.&#xD;
&#xD;
               -  If located in a previously irradiated area, a tumor lesion is considered a&#xD;
                  measurable/target lesion only if subsequent disease progression in the lesion has&#xD;
                  been documented at least 90 days following completion of radiotherapy.&#xD;
&#xD;
          -  Adequate organ and bone marrow function ≤ 14 days prior to first dose of&#xD;
             protocol-indicated treatment:&#xD;
&#xD;
               -  White blood cell count (WBC) ≥ 2,000/mm3&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500/mm3&#xD;
&#xD;
               -  Platelets ≥ 75,000/mm3&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dL.&#xD;
&#xD;
               -  Serum creatinine ≤ 2.0x upper limit of normal (ULN), or calculated creatinine&#xD;
                  clearance (CrCl) &gt; 40 mL/min per the Cockcroft-Gault formula (Appendix 1).&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5x ULN (except patients with Gilbert Syndrome, who must have&#xD;
                  total bilirubin &lt; 3.0 mg/dL).&#xD;
&#xD;
               -  AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤ 3.0x ULN (≤&#xD;
                  5.0x ULN in those with hepatic metastases)&#xD;
&#xD;
          -  Acceptable troponin level ≤ 14 days prior to first dose of protocol-indicated&#xD;
             treatment:&#xD;
&#xD;
               -  Troponin T (TnT) or I (TnI) ≤ 2× institutional ULN.&#xD;
&#xD;
               -  Subjects with TnT or TnI levels between &gt;1 to 2× ULN will be permitted if repeat&#xD;
                  levels within 24 hours are ≤ 1x ULN.&#xD;
&#xD;
               -  If TnT or TnI levels are &gt;1 to 2× ULN within 24 hours, the subject may undergo a&#xD;
                  cardiac evaluation and be considered for treatment based on the discretion of the&#xD;
                  PI.&#xD;
&#xD;
               -  When repeat levels within 24 hours are not available, a repeat test should be&#xD;
                  conducted as soon as possible.&#xD;
&#xD;
               -  If TnT or TnI repeat levels beyond 24 hours are &lt; 2x ULN, the subject may undergo&#xD;
                  a cardiac evaluation and be considered for treatment, based on the discretion of&#xD;
                  the PI.&#xD;
&#xD;
          -  Arm A: Corrected QT interval (QTc) by Fridericia's method (QTcF) assessed by&#xD;
             electrocardiogram (ECG) completed ≤ 28 days before initiation of protocol treatment&#xD;
&#xD;
             • QTcF ≤ 480 msec&#xD;
&#xD;
          -  Tumor tissue from a biopsy or resection obtained since completion of the last systemic&#xD;
             therapy must be available for analysis of MHC-II status and for biomarker analysis. If&#xD;
             a sample is not available or if the quantity or quality of tissue is insufficient to&#xD;
             provide adequate results, an additional biopsy may be performed for MHC-II analysis.&#xD;
             Patients cannot be enrolled on the study unless MHC-II is known.&#xD;
&#xD;
          -  Women must not be breastfeeding&#xD;
&#xD;
          -  A woman of childbearing potential must have a negative serum pregnancy test within 14&#xD;
             days prior to receiving first dose of protocol-indicated treatment, and must agree to&#xD;
             follow instructions for using acceptable contraception (Appendix 4) from the time of&#xD;
             signing consent, and for 165 days (24 weeks) after her last dose of protocol-indicated&#xD;
             treatment.&#xD;
&#xD;
          -  A man able to father children who is sexually active with a woman of childbearing&#xD;
             potential must agree to follow instructions for using acceptable contraception from&#xD;
             the time of signing consent, and for 225 days (33 weeks) after his last dose of&#xD;
             protocol-indicated treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with uveal melanoma.&#xD;
&#xD;
          -  Prior systemic anticancer therapy for unresectable or metastatic melanoma.&#xD;
&#xD;
          -  Prior treatment with LAG-3 targeted agents.&#xD;
&#xD;
          -  Subjects with active, known, or suspected autoimmune disease. Subjects with type I&#xD;
             diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders&#xD;
             (such as vitiligo, psoriasis or alopecia) not requiring systemic treatment, or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to enroll.&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease including, but not limited to, any&#xD;
             of the following:&#xD;
&#xD;
               -  Myocardial infarction (MI) or stroke/transient ischemic attack (TIA) within the 6&#xD;
                  months prior to consent.&#xD;
&#xD;
               -  Uncontrolled angina within the 3 months prior to consent.&#xD;
&#xD;
               -  Any history of clinically significant arrhythmias (such as ventricular&#xD;
                  tachycardia, ventricular fibrillation, torsades de pointes, or poorly controlled&#xD;
                  atrial fibrillation).&#xD;
&#xD;
               -  QTc prolongation &gt; 480 msec.&#xD;
&#xD;
               -  History of other clinically significant cardiovascular disease (i.e.,&#xD;
                  cardiomyopathy, congestive heart failure with New York Heart Association [NYHA]&#xD;
                  functional classification III-IV, pericarditis, significant pericardial effusion,&#xD;
                  significant coronary stent occlusion, poorly controlled deep venous thrombosis,&#xD;
                  etc).&#xD;
&#xD;
               -  Cardiovascular disease-related requirement for daily supplemental oxygen.&#xD;
&#xD;
               -  History of two or more myocardial infarctions OR two or more coronary&#xD;
                  revascularization procedures.&#xD;
&#xD;
               -  Subjects with history of myocarditis, regardless of etiology.&#xD;
&#xD;
          -  A confirmed history of encephalitis, meningitis, or uncontrolled seizures in the year&#xD;
             prior to informed consent.&#xD;
&#xD;
          -  Participants with a condition requiring systemic treatment with either corticosteroids&#xD;
             (&gt;10 mg daily prednisone or equivalent) or other immunosuppressive medications within&#xD;
             14 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid&#xD;
             doses &gt;10 mg daily prednisone or equivalent, are permitted in the absence of active&#xD;
             autoimmune disease.&#xD;
&#xD;
          -  Subjects with active central nervous system (CNS) metastases, active brain metastases&#xD;
             or leptomeningeal metastatic foci. For the subjects with brain metastases, if they are&#xD;
             asymptomatic, they are eligible to participate in this study. If participants have&#xD;
             received treatment for brain metastases and have no clinical evidence of progressive&#xD;
             disease at least 1 week after completion of treatment for brain metastases and within&#xD;
             28 days prior to the first dose of protocol-indicated treatment on this study, they&#xD;
             are eligible to participate in this study.&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS).&#xD;
&#xD;
          -  Known history of hepatitis B or hepatitis C.&#xD;
&#xD;
          -  Any significant medical condition, laboratory abnormality, or psychiatric illness,&#xD;
             that would prevent the subject from participating in the study or place the subject at&#xD;
             unacceptable risk if he/she were to participate in the study, or any condition that&#xD;
             confounds the ability to interpret data from the study.&#xD;
&#xD;
          -  Subjects with life expectancy &lt; 6 months.&#xD;
&#xD;
          -  Subjects receiving any other investigational or standard antineoplastic agents.&#xD;
&#xD;
          -  Prior malignancy active within the previous 3 years except for locally curable cancers&#xD;
             that have been apparently cured, such as basal or squamous cell skin cancer,&#xD;
             superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.&#xD;
&#xD;
          -  Prisoners or participants who are involuntarily incarcerated.&#xD;
&#xD;
          -  Participants who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (e.g. infectious disease) illness.&#xD;
&#xD;
          -  Psychological, familial, sociological, or geographical conditions that potentially&#xD;
             hamper compliance with the study protocol and follow-up schedule; those conditions&#xD;
             should be discussed with the participant before registration in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 26, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <results_first_submitted>February 12, 2021</results_first_submitted>
  <results_first_submitted_qc>February 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2021</results_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Elizabeth Davis</investigator_full_name>
    <investigator_title>Sponsor Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT03724968/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study stopped early due to loss of funding. Participants were recruited at Vanderbilt-Ingram Cancer Center in Nashville, TN from January 2019 to April 2020. Although there were 2 study arms (Arm A and Arm B), only 2 participants were enrolled and both were enrolled onto Arm B.</recruitment_details>
      <pre_assignment_details>Three participants were consented to take part in this study and 1 participant was determined to be ineligible. This study closed early due to low accrual. Both participants were assigned to Arm B. Since only 2 participants were enrolled and both were on Arm B, a statistical analysis cannot be done and some outcome measures can't be reported.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A</title>
          <description>Nivolumab and Relatlimab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Relatlimab: Relatlimab will be given by vein on day 1 of each 28-day cycle</description>
        </group>
        <group group_id="P2">
          <title>Arm B</title>
          <description>Nivolumab and Ipilimumab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Ipilimumab: Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insurance issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study closed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study stopped early due to low accrual and no participants were enrolled to Arm A</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>Nivolumab and Relatlimab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Relatlimab: Relatlimab will be given by vein on day 1 of each 28-day cycle</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>Nivolumab and Ipilimumab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Ipilimumab: Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Activated GZMB+ CD8+T-cell Density Intratumorally, of Two Immunotherapy Regimens</title>
        <time_frame>Approximately 16 months</time_frame>
        <population>Due to loss of funding data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Nivolumab and Relatlimab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Relatlimab: Relatlimab will be given by vein on day 1 of each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Nivolumab and Ipilimumab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Ipilimumab: Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Activated GZMB+ CD8+T-cell Density Intratumorally, of Two Immunotherapy Regimens</title>
          <population>Due to loss of funding data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <time_frame>Approximately 16 months</time_frame>
        <population>Due to loss of funding data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Nivolumab and Relatlimab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Relatlimab: Relatlimab will be given by vein on day 1 of each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Nivolumab and Ipilimumab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Ipilimumab: Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <population>Due to loss of funding data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression Free Survival</title>
        <time_frame>Approximately 16 months</time_frame>
        <population>Due to loss of funding data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Nivolumab and Relatlimab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Relatlimab: Relatlimab will be given by vein on day 1 of each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Nivolumab and Ipilimumab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Ipilimumab: Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression Free Survival</title>
          <population>Due to loss of funding data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival</title>
        <time_frame>Approximately 16 months</time_frame>
        <population>Due to loss of funding data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Nivolumab and Relatlimab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Relatlimab: Relatlimab will be given by vein on day 1 of each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Nivolumab and Ipilimumab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Ipilimumab: Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival</title>
          <population>Due to loss of funding data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 5.0</title>
        <time_frame>Up to 30 days from last dose of drugs (average of 13 cycles)</time_frame>
        <population>Due to loss of funding data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>Nivolumab and Relatlimab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Relatlimab: Relatlimab will be given by vein on day 1 of each 28-day cycle</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Nivolumab and Ipilimumab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Ipilimumab: Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 5.0</title>
          <population>Due to loss of funding data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 17 months</time_frame>
      <desc>This study was terminated due to loss of funding and not participants were enrolled onto Arm A</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>Nivolumab and Relatlimab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Relatlimab: Relatlimab will be given by vein on day 1 of each 28-day cycle</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>Nivolumab and Ipilimumab&#xD;
Nivolumab: Nivolumab will be given by vein on day 1 of each cycle.&#xD;
Ipilimumab: Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE Version 5.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTCAE Version 5.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Limb edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Teresa Melton</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>6159367423</phone>
      <email>teresa.melton@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

